Aug. 10 at 8:27 PM
$RNAZ It has been more than a year since the last meaningful clinical update, and shareholders are still waiting.
The company previously said it had enough cash to fund operations through the end of 2026 and guided toward starting dosing in the first half of the year. Yet here we are, with no clear confirmation of first patient dosing.
Now the CEO comes out talking about being open to partnerships and investment, while shareholders continue to face dilution, delays, and vague promises.
In my opinion, they are selling hope more than execution.
Soon:
$2.X stock price.❤️❤️❤️
